Chicago Capital, LLC Outlook Therapeutics, Inc. Transaction History

Chicago Capital, LLC

  • $3.33 Billion
  • Q2 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2019

Oct 29, 2019
SELL
$1.32 - $2.63 $25,674 - $51,153
-19,450 Closed
0 $0
Q2 2019

Jul 11, 2019
BUY
$0.91 - $7.68 $17,699 - $149,376
19,450 New
19,450 $40,000

Others Institutions Holding OTLK

# of Institutions
3
Shares Held
31.5K
Call Options Held
0
Put Options Held
0
View Full List

About Outlook Therapeutics, Inc.

OTLK Quotes by TradingView
  • Ticker OTLK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 226,144,992
  • Market Cap $1.19B
  • Description
  • Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-relate...
More about OTLK
Track This Portfolio

Track Chicago Capital, LLC Portfolio

Follow Chicago Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Chicago Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Chicago Capital, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email